By Ilan Zipkin
Staff Writer

Companies facing the decision to negotiate licenses on terms they deem unfavorable, or trying to fight back against patent infringement claims, may have to take a hard look at the example provided by CellPro Inc., which last week became one of the small number of biotech companies forced into bankruptcy.